Global Regenerative Medicine For Cartilage Market Size 2024, Forecast To 2033

The regenerative medicine for cartilage market has experienced robust growth, progressing from $4.24 billion in 2023 to $4.48 billion in 2024, demonstrating a notable compound annual growth rate (CAGR) of 5.6%. The growth in the historical period is linked to the regenerative medicine market resulting from the rising prevalence of chronic diseases, growth in emerging markets, the implementation of the 21st Century Cures Act, rapid growth in the aging population, and improvements in healthcare awareness and expenditure. Moving into 2028, the market is expected to sustain strong growth, reaching $5.64 billion at a consistent CAGR of 5.9%. The projected growth is driven by the rising demand for organ transplantations, increased healthcare expenditure, technological advancements in regenerative medicines, growing investments in regenerative medicine research, and lifestyle changes. Notable trends in the forecast period include the growing use of mesenchymal stem cell technology, increased research and development on novel gene therapy techniques, advancements in technology transfer and clinical translation, rising strategic collaborations, partnerships, and agreements, the growth and advent of new companies, the role of injectable hydrogel in cartilage repair as a regenerative medicine, and global research initiatives and funding.